Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Current Assets (2016 - 2025)

Cytosorbents' Current Assets history spans 15 years, with the latest figure at $20.6 million for Q4 2025.

  • Quarterly results put Current Assets at $20.6 million for Q4 2025, down 4.49% from a year ago — trailing twelve months through Dec 2025 was $20.6 million (down 4.49% YoY), and the annual figure for FY2025 was $20.6 million, down 4.49%.
  • Current Assets for Q4 2025 was $20.6 million at Cytosorbents, down from $21.3 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $79.6 million in Q1 2021 to a low of $16.6 million in Q3 2024.
  • The 5-year median for Current Assets is $25.4 million (2023), against an average of $36.2 million.
  • The sharpest move saw Current Assets skyrocketed 112.19% in 2021, then plummeted 55.49% in 2022.
  • Year by year, Current Assets stood at $64.3 million in 2021, then plummeted by 47.5% to $33.8 million in 2022, then decreased by 24.77% to $25.4 million in 2023, then decreased by 14.94% to $21.6 million in 2024, then fell by 4.49% to $20.6 million in 2025.
  • According to Business Quant data, Current Assets over the past three periods came in at $20.6 million, $21.3 million, and $23.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.